CureDuchenne Invests $1M in Gennao Bio’s Effort to Find Therapies
Genetic medicines company Gennao Bio will use a $1 million CureDuchenne Ventures investment to help expand its gene monoclonal antibody (GMAB) platform technology, which is now applied to rare muscle disorders, including Duchenne muscular dystrophy (DMD). The initial focus of the nonviral delivery system Gennao Bio is…